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Background: The aim of this study was to evaluate the efficacy and safety of neoadjuvant chemo-
therapy with infusional 5-fluorouracil (5-FU), adriamycin and cyclophosphamide (iFAC) in locally
advanced breast cancer (LABC).
Patients and methods: Eighty-two LABC patients were treated with neoadjuvant iFAC chemotherapy
including infusional 5-FU (1000 mg/m2, continuous intravenous infusion, days 1–3), adriamycin (40
mg/m2, intravenous bolus, day 1) and cyclophosphamide (600 mg/m2, intravenous bolus, day 1) every
3 weeks until maximum tumor response. Patients subsequently received surgery, adjuvant chemo-
therapy, radiotherapy and hormonal therapy as appropriate.
Results: Downstaging occurred in 71 of the 82 patients (86.6%). Seventy-two patients (67 patients
with downstaging and five patients without downstaging) were resectable (resectability rate, 87.8%).
The clinical response rate was 84.2%, with a complete response (CR) rate of 17.1% and a pathological
CR rate of 7.8%. During 891 cycles of chemotherapy, the most common grade 3/4 hematological
toxicity was leukopenia (36.0%). There were no treatment-related deaths. The median follow-up period
was 51 months, with a median overall survival (OS) of 66 months, and a 5 year OS rate of 50.9% for all
patients. The 5 year OS and disease-free survival (DFS) rates of the 64 patients who underwent surgery
were 55.8% and 44.7%, respectively.
Conclusions: Neoadjuvant chemotherapy with iFAC had a comparable response rate and DFS to the
conventional bolus FAC regimen, with an acceptable toxicity in LABC using the AJCC 2002 staging
system. An early response to neoadjuvant iFAC was a favorable prognostic factor.
Key words: adriamycin, cyclophosphamide, infusional 5-fluorouracil, locally advanced breast cancer,
neoadjuvant chemotherapy
Introduction
Achieving local and distant disease control in locally advanced
breast cancer (LABC) remains a challenge despite the decreas-
ing incidence of this cancer. Controversy still exists in the very
definition of LABC. Most reports include inoperable stage IIIB
in LABC, while others have included either operable stage III
or stage IIIC with a positive supraclavicular node [1].
Neoadjuvant chemotherapy followed by locoregional therapy
is a standard treatment in LABC. The 5 year overall survival
rate has improved from 10–20% with local therapy alone to
30–60% with the multidisciplinary approach [2]. The most ef-
fective regimens usually contain adriamycin. Generally, three to
four treatment cycles have been reported to induce the clinical
response rate of 50–90% and a pathological complete response
(pCR) rate <20% [3, 4]. A combined i.v. bolus 5-fluorouracil
(5-FU), adriamycin and cyclophosphamide (FAC) regimen has
been investigated in a neoadjuvant setting [5] because it was
previously reported to induce a good tumor response in meta-
static breast cancer [6, 7]. More recently, a bolus FAC regimen
has been widely used as neoadjuvant chemotherapy in LABC
[5, 8, 9].
The duration of 5-FU exposure is an important determinant
of cytotoxicity, yet this agent has a short plasma half-life of
approximately 11 min [10]. It was hypothesized that continuous
i.v. infusion of 5-FU would overcome this limitation, and the
prediction was validated by the observation of improved in vitro
sensitivity to prolonged low-dose 5-FU exposure versus short
high-dose exposure [11]. However, only a few studies have
evaluated infusional FAC (iFAC) in the neoadjuvant setting of
LABC.
The present study was designed to evaluate the efficacy and
safety of an iFAC regimen as neoadjuvant chemotherapy in
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LABC, and to identify the predictive and prognostic factors
for response and survival with this regimen. The primary
endpoint of this study was response rate and the secondary
endpoints were downstaging rate, disease-free survival, overall
survival, toxicity and dose intensity.
Patients and methods
Eligibility criteria
LABC was defined as follows for this study: tumor ‡5cm with metastasis to
the ipsilateral axillary nodes; tumor with direct extension to the chest wall or
skin; tumor with metastasis to the ipsilateral fixed axillary/ipsilateral internal
mammary/ipsilateral supraclavicular nodes. Patients with LABC and inflam-
matory breast cancer (IBC) were eligible for this study. Other eligibility
criteria included age £70 years, histologically proven infiltrating ductual or
lobular carcinoma, Eastern Oncology Cooperative Group (ECOG) perform-
ance status £2, adequate bone marrow (neutrophils ‡2 · 103/ll, platelets
‡100 · 103/ll, Hb ‡10.0 g/dl), renal (serum creatinine £1.5 times upper
normal limit) and liver function [serum bilirubin £1.5 times upper normal
limit, and aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) £1.5 times upper normal limit], and no previous chemotherapy, radio-
therapy or hormone therapy. Patients with other malignancies or bilateral
breast cancers were excluded from this study. Eighty-two patients were en-
rolled between June 1991 and June 2001. As the staging system for breast
cancer was changed during the enrollment period, patients were restaged
using the American Joint Cancer Committee (AJCC) staging system revised
in 2002 [12].
Treatment scheme
The iFAC regimen was administered according to the following schedule:
5-FU 1000 mg/m2 24 h continuous infusion on days 1–3, adriamycin 40
mg/m2 i.v. bolus injection on day 1 and cyclophosphamide 600 mg/m2 i.v.
bolus on day 1. The treatment was repeated every 3 weeks. When the tumor
response reached a maximum, as determined by there being no change in the
tumor size for two consecutive treatment cycles, the resectability was as-
sessed by an oncological surgeon. Criteria of resectability were determined
as follows: no distant metastasis, no extensive involvement of the skin, no
change of the inflammatory cancer and no fixation of axillary nodes to one
another or to other structures. After surgery, adjuvant chemotherapy with
iFAC was followed until a maximum of 12 cycles including neoadjuvant
chemotherapy. Radiotherapy was performed with a dose of 50.4 Gy over
5.5 weeks. The irradiated volume included the chest wall, ipsilateral
internal mammary node and ipsilateral supraclavicular node areas.
If the tumor was unresectable after iFAC, chemotherapy was continued
with a salvage regimen. Hormonal treatment was added in those patients
who were hormonal receptor positive or in a postmenopausal state. The
treatment scheme is summarized in Figure 1.
Response and toxicity evaluation
Tumor measurements were performed by physical examination, mammo-
graphy and/or ultrasonography and chest CT at the baseline and after every
third cycle, or whenever needed. The clinical response was defined
according to the World Health Organization (WHO) criteria [13]. An early
response was defined as a maximum clinical response within three cycles
of iFAC chemotherapy, and a late response was defined as a maximum
clinical response occurring after three cycles. The late and no response
groups were gathered into a single ‘late/no response group’. After surgery,
the residual disease was dichotomized into microscopic residual disease
(microRD, breast tumor £1 cm and negative axillary node) and macroscopic
residual disease (macroRD, breast tumor >1 cm or positive axillary node).
pCR and microRD were included together in the good pathological
response group.
Toxicity was graded using the WHO criteria [13]. Granulocyte colony-
stimulating factor (G-CSF) was administered in cases of grade 3/4 neutro-
penia, and the subsequent cycle was delayed until complete recovery. The
dose administered was reduced by 25% if a grade 3/4 non-hematological
toxicity occurred or was sustained for >2 weeks.
Follow-up evaluation after completion of anticancer
treatment
The patients were evaluated every 6 months after completion of treatment. If
possible, all suspected recurrences were confirmed by biopsy during the
follow-up period. Typical nodules in the liver or the lung, indicated by
imaging studies, or lytic areas on the bone indicated by radioisotope
bone scan and plain radiographs, were accepted as recurrence without
histological confirmation. Locoregional recurrence was defined as recur-
rence in the chest wall, breast, axillary node or ipsilateral supraclavicular
node areas. Disease-free survival (DFS) was defined as the time from cura-
tive surgery to cancer recurrence, occurrence of a secondary primary cancer
or death without evidence of recurrence. Overall survival (OS) was defined
as the time from neoadjuvant chemotherapy to death from all causes.
Statistical methods
All statistical calculations were carried out using SPSS Windows version
11.0 (SPSS Inc., USA). All P-values were two-sided and the a-value was set
at 0.05. Survival was calculated using the Kaplan–Meier method. A log-rank
test was used to compare survival between groups. Prognostic variables were
submitted to multivariate analysis using Cox’s proportional hazard regres-
sion model. Predictive factors for responsiveness were analyzed using a v2
test/Fisher’s exact test and a logistic regression.
Results
Characteristics of eligible patients
Between June 1991 and June 2001, 82 LABC patients were
enrolled in this study. The median follow-up period was 51
months (range 7–122 months) by 31 December 2003. The
median age was 47 years (range 29–70 years). All tumors ex-
cept two infiltrating lobular carcinomas were infiltrating ductal
Figure 1. Treatment scheme and results.
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carcinomas. The ECOG performance status was between 0 and
1 in all patients. Twenty patients (24.4%) had IBC, and 42, 30
and 10 patients were in clinical stages IIIA, IIIB and IIIC, re-
spectively, based on the AJCC 2002 staging system. Detailed
patient characteristics are summarized in Table 1.
Treatment results
As shown in the gray shaded region of Table 2, downstaging was
observed in 86.6% of patients (71/82). Four of the 71 down-
staged patients were still unresectable because of an increased
axillary node size (one patient), new breast lesions (two pa-
tients) or an unchanged fixed axillary node (one patient). In
contrast, five of 11 patients without downstaging became resect-
able owing to decreased breast tumor size. As a result, 72
patients (67 patients with and five patients without downstaging)
were respectable (resectability rate, 87.8%).
Eight of the 72 resectable patients refused surgery. All con-
senting patients underwent a modified radical mastectomy with
an axillary lymph node dissection. The distribution of the path-
ological stages is summarized in Table 2. After adjuvant chemo-
therapy, 50.0% of the patients (32/64) received radiotherapy at
a median dose of 50.4 Gy (range 48.6–75.6 Gy).
Ten unresectable patients received salvage chemotherapy
with a platinum- or taxane-based regimen with or without
radiation. Five of the 10 unresectable patients underwent sur-
gery after salvage treatment. Figure 1 provides an overview of
the treatment results.
Clinical and pathological response to
iFAC chemotherapy
Clinical response was evaluated in breast tumors (82 patients),
axillary nodes (69 patients) and supraclavicular nodes (10
patients). The clinical response rates were 84.4% for breast
tumor (cCR, 25.6%; cPR, 58.8%), 82.8% for axillary nodes
(cCR, 55.7%; cPR, 27.1%) and 100% for supraclavicular nodes
(cCR, 100%). The overall response rate (ORR) was 84.2%
(cCR, 17.1%; cPR, 67.1%). The pCR rates were 10.9% for
breast tumor and 26.6% for axillary nodes. Five patients
(7.8%, 5/64) achieved a pCR in both breast tumor and axillary
nodes, and seven (10.9%) of the 64 patients who underwent
surgery achieved a good pathological response (Table 3).
A discrepancy was noted between cCR and pCR in that only
four of the 14 cCR patients had pCR. Of the remaining 10
patients, three had a residual breast tumor without axillary
lymph node involvement, two had axillary lymph node involve-
ment without a residual tumor in the breast and five had both
a residual tumor in the breast and axillary lymph nodes. In
contrast, four of five pCR patients were assessed as having
a cCR and the remaining patient was assessed as having a cPR.
Recurrence pattern and disease-free survival
At a median follow-up duration of 51 months (range 7–122
months), 35 (54.7%) of the 64 operated patients experienced
recurrence. The most common locoregional and distant recur-
rence sites were the chest wall and the bone, respectively. The
Table 1. Patient characteristics
Number Percentage
Total number of patients 82
Median age (range) (years) 47 (29–70)
Initial clinical stage
IIIA 42 51.3
T1N2M0 1
T2N2M0 11
T3N1M0 21
T3N2M0 9
IIIB 30 36.5
T4N0M0 14
T4N1M0 10
T4N2M0 6
IIIC 10 12.2
T2N3M0 5
T2N3M0 5
Inflammatory breast cancer 20 24.4
Median initial tumor size (range) (cm) 7 (1.5–18)
Pathology
Infiltrating ductal carcinoma 80 97.5
Infiltrating lobular carcinoma 2 2.5
Estrogen/progesterone receptor
Positive/positive 17 52.4
Positive/negative 3 7.1
Negative/positive 0 0
Negative/negative 22 40.5
Unknown 40 –
Menopause state
Premenopause 44 53.7
Postmenopause 38 46.3
Table 2. Downstaging clinical stage after neoadjuvant chemotherapy
Initial
stage
No. of
patients
Clinical stage after neoadjuvant chemotherapy
0 I IIA IIB IIIA IIIB
IIIA 42 8 3 18 7 6 0
IIIB 30 3 1 14 7 0 5
IIIC 10 3 1 4 0 2 0
Pathological stage after surgery
0 I IIA IIB IIIA IIIB
IIIA 32 2 2 12 8 7 1
IIIB 25 2 0 7 7 6 3
IIIC 7 3 0 3 0 7 0
The numbers in the shaded region represent the downstaged patients.
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locoregional, distant and combined recurrences occurred in 10
(15.6%), 17 (26.6%) and eight (12.5%) patients, respectively.
Six of the 10 patients with locoregional recurrence showed a sub-
sequent systemic recurrence, whereas a delayed locoregional
recurrence was observed in only one of 17 initial systemic recur-
rences. The median DFS duration of the 64 operated patients
was 45 months [95% confidence interval (CI) 17–73]. The 5
year locoregional recurrence-free survival (LRFS), the 5 year
distant recurrence-free survival (DRFS) and the 5 year DFS rates
were 68.5%, 51.3% and 44.7%, respectively.
Overall survival
At a median follow-up duration of 51 months (range 7–122
months), 41 (50%) of the 82 patients had died. Forty patients
died from disease progression and one died from acute myocar-
dial infarction. The median OS duration of the patients was 66
months (95% CI 43–89), and their 5 and 10 year OS rates were
50.9% and 37.4%, respectively (Figure 2). The median OS
duration of the 64 operated patients was 89 months (95% CI
43–129), and their 5 and 10 year OS rates were 57.7% and
44.1%, respectively (Figure 2).
Toxicity profile
The dominating toxicity was myelosuppression. Of a total of
891 cycles, grade 3/4 leukopenia occurred in 36.0%, anemia in
0.8% and thrombocytopenia in 0.5%. Other serious toxicities in-
cluded one episode of pneumonia with septic shock and three
cases of congestive heart failure (CHF). However, there were
no treatment-related deaths. The three CHFs occurred after com-
pletion of iFAC chemotherapy, and all three patients received
cumulative doxorubicin doses of 480 mg/m2. Heart failure de-
veloped at 2 months (two patients) and 46 months (one patient)
after completion of iFAC. Oral mucositis and diarrhea were mild.
Dose intensity
The median duration of the neoadjuvant chemotherapy was 10
weeks (range 7–23 weeks) with a median number of three cycles
(range two to six). For neoadjuvant chemotherapy, the relative
dose intensities (RDIs) were 1.0 (range 0.5–1.0), 1.0 (range 0.6–
1.0) and 1.0 (range 0.5–1.0) for 5-FU, adriamycin and cyclo-
phosphamide, respectively. For adjuvant chemotherapy, the
RDIs were 0.9 (range 0.6–1.0), 0.9 (range 0.4–1.0) and 0.9
(range 0.4–1.0) for 5-FU, adriamycin and cyclophosphamide,
respectively. The RDIs of the combined iFAC regimen in the
neoadjuvant and adjuvant settings were 0.98 (range 0.58–1.00)
and 0.91 (range 0.91–1.00), respectively.
Prognostic factors for recurrence and survival
Initial tumor size, IBC, initial clinical stage/response and patho-
logical stage/response were evaluated as prognosticators.
Table 4 summarizes the significant factors by univariate analy-
sis. Multivariate analysis identified the following independent
favorable prognostic factors (Table 4): clinical response for
DRFS [hazard ratio (HR) = 3.6, P = 0.03] and OS (HR = 3.7,
P = 0.04); early response for LRFS (HR = 4.1, P = 0.002),
DRFS (HR = 3.1, P = 0.004), DFS (HR = 3.2, P = 0.01) and
OS (HR = 3.6, P = 0.002).
An early response was observed in 51 of the 69 responders
(73.9%). The early response subgroup represented prolonged
LRFS (P < 0.000), DRFS (P = 0.002), DFS (P < 0.000)
and OS (P < 0.000) compared with the late response subgroup
(Figure 3).
Predictive factors for early response
In the whole group, early and late/no responses were observed
in 51 (62.2%) and 31 (37.8%) patients, respectively. The follow-
ing variables were evaluated as predictive factors for early
response: initial tumor size, IBC and initial stage. The initial
tumor size and the initial N stage were significant predictors by
univariate analysis (Table 5). Only a small initial tumor size
(£10 cm in long dimension) was a significant favorable pre-
dictor for early response according to multivariate analysis
(HR = 0.14, P = 0.001).
Discussion
Continuous venous infusion increases dose intensity and pro-
longs exposure of cancer cells to an active drug [10]. An initial
investigation of continuous infusion of 5-FU in colorectal cancer
Table 3. Response rate to neoadjuvant iFAC chemotherapy
Clinical response
(n = 82)
Pathological response
(n = 64)
Number (%) Number (%)
Primary tumor n = 82 n = 64
CR 21 (25.6) pCR 7 (10.9)
PR 49 (58.8) No pCR 57 (89.1)
SD 6 (7.3) –
PD 6 (7.3) –
AXLN n = 69 n = 64
CR 41 (59.4) pCR 17 (26.6)
PR 18 (26.1) No pCR 47 (73.4)
SD 8 (11.6) –
PD 2 (2.9) –
SCL (n = 10)
CR 10 (100) –
Total responsea
CR 14 (17.1) pCR 5 (7.8)
PR 55 (67.1) microRD 2 (3.1)
SD 6 (7.3) macroRD 57 (89.1)
PD 7 (8.5) –
AXLN, axillary lymph node; SCL, supraclavicular node; CR, complete
response; PR, partial response; SD, stable disease; PD, progressive
disease; pCR, pathological complete response; micro/macroRD,
micro/macro residual disease.
aTotal response was assessed by the summation of responses in primary
tumor, AXLN and SCL based on the WHO response criteria.
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demonstrated a high response and less bone marrow toxicity
than administration of bolus 5-FU because of the different mode
of action [14]. In a prior modified FAM (5-FU, adriamycin,
mitomycin-C) trial in advanced gastric cancer at our institute,
a trend of prolonged progression-free survival was observed
for continuous infusion of 5-FU compared with bolus injection
[15]. Later, a similar investigation in metastatic breast cancer re-
sulted in a high response rate of 75% [16].
A bolus FAC regimen is one of the most commonly used
treatments in LABC, with a reported clinical response of 72–
88% and a pCR of 8–9% [5, 8, 9]. Even with a larger tumor size
and a more advanced stage according to the AJCC 2002 staging
system, the response rate and DFS of this trial with iFAC were
similar to those of the M. D. Anderson Cancer Center clinical
trial with a bolus FAC regimen [5]. Another bolus FAC trial in
LABC reported a 5 year OS rate of 46% [9]. The 5 year OS rates
of stage IIIA (47%) and IIIB (44%) reported by the National
Cancer Institute [17] were similar to our 5 year OS rates for
stage IIIA (57.6%), IIIB (44.8%) and IIIC (47.9%) patients.
A high pCR of 16% was induced by MVAC (methotrexate,
vinblastine, doxorubicin, cisplatin) with a 5 year DFS of 51%.
However, because of myelosuppression and diarrhea, only 31%
of the patients in that trial were able to complete the intended
six cycles of adjuvant MVAC chemotherapy [18]. CVAP
(cyclophosphamide, vincristine, doxorubicin, prednisolone)
also induced a high pCR of 16% but the long-term survival
results are awaited [19]. Recently, sequential docetaxel after
anthracycline-based neoadjuvant chemotherapy was found to
enhance the clinical response and pathological complete
response rates significantly in two randomized phase III trials
[19, 20]. However, it should be noted that the initial use of
taxanes in LABC faces limitations such as loss of potential
second-line drugs in the anthracycline-resistant cases. No
data are yet available regarding the long-term survival of this
treatment.
The randomized phase III Trial of Preoperative Infusional
Chemotherapy (TOPIC1) [21] revealed that neoadjuvant con-
tinuous infusional 5-FU-based chemotherapy (5-FU, cisplatin,
epirubicin) was no more effective than conventional bolus AC
(adriamycin, cyclophosphamide) for early breast cancer. In
TOPIC1, the inconvenience of continuous infusional 5-FU could
not be justified by a non-significant increase in survival. Our trial
is different from TOPIC1 in that infusional 5-FU-based chemo-
therapy was given to inoperable LABC patients. Infusional
5-FU-based chemotherapy might be overtreatment in cases of
operable early breast cancer, and be needed instead for more
Figure 2. Survivals of (A) all 82 patients and (B) 64 operated patients. DFS, disease-free survival; OS, overall survival.
Table 4. Multivariate analysis of prognostic factors using Cox’s proportional hazard model
Variables LRFS DRFS DFS OS
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Initial tumor size (£10 cm vs >10 cm) 0.7 (0.2–2.1) 0.56 – – 1.6 (0.7–3.9) 0.26 – –
Clinical response (CR/PR vs SD/PD) 3.4 (1.0–12.1) 0.06 3.6 (1.1–11.8) 0.03 2.6 (0.8–9.0) 0.12 3.7 (1.1–12.4) 0.04
Early responsiveness (ER vs LR/NR) 4.1 (1.7–10.3) 0.002 3.1 (1.4–6.7) 0.004 3.2 (1.4–7.3) 0.01 3.6 (1.6–8.3) 0.002
Pathological T stage (T1–T2 vs T3–T4) – – – – – – 1.5 (0.7–3.4) 0.33
Pathological N stage (N0 vs N1–N3) 1.3 (0.5–3.6) 0.63 – – 2.0 (0.8–5.4) 0.15 – –
LRFS, locoregional recurrence-free survival; DRFS, distant recurrence-free survival; DFS, disease-free survival; OS, overall survival; HR, hazard ratio;
CI, confidence interval; ER, early response; LR, late response; NR, no response.
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advanced breast cancers, such as inoperable LABC, as reported
previously in an advanced and locally advanced breast cancer
trial [22].
The toxicities of iFAC chemotherapy were generally mild
and acceptable. The major toxicity was bone marrow suppres-
sion, which was manageable with G-CSF. Continuous infusion
of 5-FU in the iFAC regimen did not cause severe oral mucositis
or diarrhea. Hand–foot syndrome was not observed. The occur-
rence of CHF (3.7%) was lower than in the bolus FAC trial
(9.1%) [5]. Continuous infusion of 5-FU showed no evidence
of enhancing anthracycline-induced CHF.
Most studies have used a fixed number of neoadjuvant chemo-
therapy cycles, usually three or four [5, 23]. However, in the
present study patients received treatment until the maximum
clinical response was achieved, regardless of the number of
cycles. The former strategy has the advantage that definitive local
therapy is not unnecessarily delayed, although it also presents the
disadvantage of missing an opportunity for optimal resection due
to insufficient response. Our strategy might improve the response
with the potential risk of development of resistant clones.
The clinical benefits of neoadjuvant chemotherapy include
downstaging, induction of resectability and breast conservation.
In the present study, downstaging and resectability rates were
high, but breast conservation was not performed. Hortobagyi
and colleagues reported that 23% of patients with stage IIB or
III tumors were potential candidates for breast conservation
[24]. The breasts of our patients were too small compared with
the breast tumor mass to conserve, and the patients did not want
to conserve the breast. This cultural trend explains the limited
use of breast conservation surgery in Korea.
The limitation of this study was that the tumor measurements
were made using classical methods, i.e. physical examination,
mammography and/or ultrasonography and chest CT. A discrep-
ancy was noted between cCR and pCR that was attributable to
overestimation of the residual tumor from chemotherapy-in-
duced fibrosis or difficulty in detecting microscopic residual
tumor by the classical evaluation methods. MRI and positron
emission tomography would be expected to increase the accu-
racy of the tumor response estimate [25, 26].
A pCR is known to represent the best outcome [27, 28]. The
good pathological response group in the present study (five
pCRs and two microRDs) also showed a trend toward better
DFS. As reported in many other studies [5, 29], our investigation
found that the clinical response was a favorable prognostic
Figure 3. Comparison of survival between early (n = 43; solid curve) and late (n = 17; broken curve) response groups of resected patients: (A) locoregional
recurrence-free survival; (B) distant recurrence-free survival; (C) disease-free survival; (D) overall survival.
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factor. The early response subgroup had a more favorable prog-
nosis than the late response subgroup. This suggests that pro-
longed preoperative chemotherapy with the same regimen has
less benefit in iFAC chemotherapy for late responders, i.e.
patients with poor response after three cycles of iFAC should
receive chemotherapy with an alternative regimen. Two possible
explanations for better outcome in the early response subgroup
are as follows: early local therapy may alter the disease course,
or an early response to iFAC may represent a biologically pre-
determined good prognosis. In the results of the National Sur-
gical Adjuvant Breast and Bowel Project B-18, which compared
pre- and postoperative chemotherapy in operable cancer, early
surgery did not alter the disease course [30]. This finding seems
to favor the second suggested explanation above. In the analysis
of predictive factors, early responsiveness inversely correlated
with initial tumor size. Thus tumor size can be considered to be
an important parameter in selecting patients for neoadjuvant
iFAC in LABC. Attempts are under way to identify the molec-
ular predictors for early response in our patients by microarray-
based comparative genomic hybridization.
In conclusion, neoadjuvant chemotherapy with iFAC had a
comparable response rate and DFS to the conventional bolus
FAC regimen, with an acceptable toxicity in LABC using the
AJCC 2002 staging system. An early response to neoadjuvant
iFAC was a favorable prognostic factor.
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